Abstract
Background & Aim Liver fibrosis screening in primary care population is a major public health issue. The FIB-4 index is a simple non-invasive fibrosis test combining age, transaminases, platelets count, developed for the diagnosis of advanced fibrosis. The aim of our study was to evaluate the interest of liver fibrosis screening using systematic calculation of FIB-4 in routine blood analysis.
Methods Between December 2018 and May 2019, we conducted a prospective screening of liver fibrosis in 134 158 patients during a medical check-up including routine blood analysis. Among these patients, 29 707 had transaminases and platelets counts available and benefited from an automatic calculation of FIB-4. Results were obtained from 21 French clinical laboratories in the Bouches du Rhône region.
Results Among the 29 707 patients, 2160 (7.3%) had significant fibrosis (FIB-4>2.67). Individual investigation of patients with FIB-4>2.67 allowed to screen 1267 (1267/2160: 59%) patients who were not managed for any liver disease.
Conclusions This work demonstrates the interest of FIB-4 for the screening of liver fibrosis in primary care population. Our study strongly supports this easy-to-implement strategy using a simple Fib-4 measure resulting from the use of available routine test results.
Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Clinical Registering Number MR-0314071019 (INDS: French National Institute for Medical Data)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.indsante.fr/fr/repertoire-public/etude-sous-mr-0314071019
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite de Protection des Personnes (CPP) Sud-Mediterranee II - Hopital Sainte Marguerite - Pavillon 9, Marseille, FRANCE (http://www.cpp-sudmed2.fr/) Decision: Exemption
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available immediately after publication with no end date to researchers who provide a methodologically sound proposal. Requests should be addressed by email to g.penaranda@alphabio.fr.
Abbreviations
- NAFLD
- non-alcoholic fatty liver disease
- AST
- aspartate aminotransferase
- ELF
- enhanced liver fibrosis
- ALT
- alanine aminotransferase
- Fibroscan
- transient elastography
- T2D
- Type 2 diabetes mellitus
- NASH
- non-alcoholic steatohepatitis
- HCV
- hepatic C virus
